News | October 01, 2021
Merck to acquire Acceleron for US $ 11.5 billion
The acquisition complements and strengthens Merck’s cardiovascular pipeline
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Lifebit's accompanying suite of AI-powered end-to-end software solutions provide faster data insights, accelerate drug discovery pipelines, and improve clinical trials success
Cobas pure provides clinical labs with access to more than 230 diagnostic tests across a wide range of disease areas including infectious diseases, oncology and cardiology
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
The cloud-based platform enables long-term brain monitoring towards personalized treatment
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Subscribe To Our Newsletter & Stay Updated
